@article{c916f60edaf04483b745ea8848fc3906,
title = "Long-acting injectable versus oral antipsychotics for schizophrenia – Authors' reply",
author = "Taishiro Kishimoto and Katsuhiko Hagi and Shunya Kurokawa and Kane, {John M.} and Correll, {Christoph U.}",
note = "Funding Information: TK reports personal fees from Banyu, Eli Lilly, Janssen, Kyowa Pharmaceutical Industry, Lundbeck, Novartis, Otsuka, Sumitomo Dainippon Pharma, and Takeda, and grants from Sumitomo Dainippon Pharma and Otsuka, outside the submitted work. KH is an employee of Sumitomo Dainippon Pharma. SK reports personal fees from Sumitomo Dainippon Pharma , Meiji Seika Pharma, and Mochida Pharmaceutical, outside the submitted work. JMK reports personal fees from Alkermes, Acadia, Sumitomo Dainippon Pharma, Intra-Cellular Therapies, Merck, Neurocrine, Reviva, Roche, Saladex, Sunovion, Takeda, Teva, and LB Pharma, and grants and personal fees from H Lundbeck, Janssen, and Otsuka, outside the submitted work. JMK is also a shareholder of LB Pharma and The Vanguard Research Group. CUC reports personal fees from Acadia, Alkermes, Allergan, Angelini, Axsome, Bristol Myers Squibb, Gedeon Richter, Intra-Cellular Therapies, Janssen, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedinCell, Medscape, Merck, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon Pharma, Sunovion, Supernus, Takeda, and Teva, and royalties from UpToDate, outside the submitted work. CUC is also a stock option holder of LB Pharma. TK and KH contributed equally to this Comment.",
year = "2021",
month = jul,
doi = "10.1016/S2215-0366(21)00203-0",
language = "English",
volume = "8",
pages = "567",
journal = "The Lancet Psychiatry",
issn = "2215-0366",
publisher = "Elsevier Limited",
number = "7",
}
